Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF JUNE 04, 2021 SAM #7125
SPECIAL NOTICE

B -- Notice of Intent to Sole Source - Whole Genome Sequencing of V. parahaemolyticus isolates in Alaskan Oysters

Notice Date
6/2/2021 10:20:11 AM
 
Notice Type
Special Notice
 
NAICS
541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
 
Contracting Office
DEPT OF COMMERCE NOAA KANSAS CITY MO 64106 USA
 
ZIP Code
64106
 
Solicitation Number
1333M2-21-Q-00965
 
Response Due
6/17/2021 8:00:00 AM
 
Archive Date
07/02/2021
 
Point of Contact
Scott Beliveau
 
E-Mail Address
scott.beliveau@noaa.gov
(scott.beliveau@noaa.gov)
 
Description
The NOAA Cooperative Oxford Laboratory (COL) is working with the Food and Drug Administration�s Center for Food Safety and Applied Nutrition (FDA CFSAN) to investigate Vibrio parahaemolyticus strains in Alaskan oysters. These bacteria are of interest to the aquaculture industry due to the capability of causing human illness, usually in the form of gastroenteritis from eating raw or undercooked seafood. The goal of this project is to investigate which strains are present in Alaskan shellfish/coastal waters to inform the industry and regulatory officials of potential risks of contamination from pathogenic strains, as well as to investigate migration of strains from the Pacific Northwest to Alaskan waters. Sampling for this project was completed in September of 2018 and 56 V. parahaemolyticus isolates were cultured in preparation for Next Generation Sequencing (NGS) analysis. Whole genome sequencing (WGS) of these isolates is required for comprehensive understanding of the strains present in the Alaskan oysters sampled, and will enable NOAA to inform stakeholders of Vibrio migrations and potential pathogenic strains isolated from Alaskan aquaculture sites.�Whole Genome Sequencing must be completed using Illumina platforms (Miseq or Novaseq instrument) for results to be congruent with current FDA sequencing methods. Additionally, the results require a quality guarantee of > 80% of bases > Q30.� Whole Genome Sequencing shall be conducted from both purifiied genomic DNA and frozen bacterial cells.�
 
Web Link
SAM.gov Permalink
(https://beta.sam.gov/opp/e76287439d1047a49f86cfbc3cdeee9a/view)
 
Record
SN06018715-F 20210604/210602230116 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.